SCHEMBL5455799

SCHEMBL5455799

CC1CCc2sc(NC(=O)C3CC3)c(C(N)=O)c2C1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 1/20 0.68
REV1 Q9UBZ9 3/20 0.65
MAPT P10636 4/20 0.59
DUSP3 P51452 1/20 0.59
PTPN5 P54829 1/20 0.59
PTPN11 Q06124 1/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
PDE4B Q07343 1/20 0.57
PDE4D Q08499 1/20 0.57
ALDH1A1 P00352 5/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
POLB P06746 1/20 0.55
KDM4E B2RXH2 3/20 0.53
THRB P10828 1/20 0.53
HSD17B10 Q99714 2/20 0.52
ATM Q13315 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HPGD P15428 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3916303 0.90 REV1 (0.79) FLT3REV1MAPTDUSP3PTPN5
SCHEMBL21597466 0.88 KDM4E (0.53) FLT3REV1MAPTDUSP3PTPN5
SCHEMBL8290721 0.87 KDM4E (0.64) FLT3REV1MAPTDUSP3PTPN5
SCHEMBL21597119 0.86 REV1 (0.53) FLT3REV1MAPTDUSP3PTPN5
SCHEMBL21603968 0.86 KDM4E (0.71) FLT3REV1MAPTALDH1A1RAB9A
SCHEMBL5453301 0.85 REV1 (0.76) FLT3REV1MAPTDUSP3PTPN5
SCHEMBL5453347 0.85 REV1 (0.76) FLT3REV1MAPTDUSP3PTPN5
SCHEMBL5460122 0.84 MEN1 (0.61) FLT3REV1MAPTDUSP3PTPN5
SCHEMBL21597710 0.82 KDM4E (0.69) MAPTKMT2AALDH1A1POLBKDM4E
SCHEMBL3922474 0.81 FLT3 (1.00) FLT3MAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885REV1 1861/4885MAPT 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.